{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"CELU","limit":50},"count":50,"signals":[{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":37,"context":"and have each indicated a willingness to continue to serve as a director, if elected. If the nominee becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our board of directors. **Nominee for Election as Class I Directors** The following table identifies our nominees for directors and their ages as of October 30, 2025, and the following biographies sets forth their princip","filed_date":"2025-11-07","accession":"0001493152-25-021208","full_text":"https://origin.rootz.global/static/filing/0001493152-25-021208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ngs, incurred in connection with the rightful enforcement of rights under this Agreement against any party hereto, and whether or not arising out of third party claims against an indemnified party. **Material Adverse Effect** means any material adverse effect on (i) the legality, validity or enforceability of any Transaction Document, (ii) the results of operations, assets, business, prospects or financial condition of","filed_date":"2025-10-28","accession":"0001493152-25-019839","full_text":"https://origin.rootz.global/static/filing/0001493152-25-019839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"Act) connected with the Company in any capacity at the time of sale. Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Purchase Price equals $1.50 per Share, subject to adju","filed_date":"2025-07-30","accession":"0001641172-25-021556","full_text":"https://origin.rootz.global/static/filing/0001641172-25-021556.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"Act) connected with the Company in any capacity at the time of sale. Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Purchase Price equals $___ per Share, subject to adjus","filed_date":"2025-07-22","accession":"0001641172-25-020580","full_text":"https://origin.rootz.global/static/filing/0001641172-25-020580.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":33,"context":"ac Limited and Genting Berhad, dated December 19, 2024 reporting two transactions.; **Item 11. Executive Compensation.** The following is a discussion and analysis of compensation arrangements of our named executive officers. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual compen","filed_date":"2025-05-21","accession":"0001641172-25-011942","full_text":"https://origin.rootz.global/static/filing/0001641172-25-011942.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":60,"context":"on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investm","filed_date":"2025-05-08","accession":"0001641172-25-009319","full_text":"https://origin.rootz.global/static/filing/0001641172-25-009319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ervices to third parties; | | | | the size of the markets for our therapeutic candidates and biomaterials products, and our ability to serve those markets; | | | | the timing of the initiation, enrollment and completion of any potential clinical trials in the United States and foreign countries; | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of","filed_date":"2025-02-13","accession":"0001493152-25-006219","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"tic candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | | | We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. | | | | Our relationship wi","filed_date":"2025-02-13","accession":"0001493152-25-006219","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":36,"context":"tock or options to purchase shares of our Class A common stock. | -123- | | **EXECUTIVE AND DIRECTOR COMPENSATION** **** The following is a discussion and analysis of compensation arrangements of our named executive officers. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual compen","filed_date":"2025-02-13","accession":"0001493152-25-006219","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006219.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"Act) connected with the Company in any capacity at the time of sale. Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Purchase Price equals $2.25 per Share and $0.125 per w","filed_date":"2025-01-03","accession":"0001493152-25-000294","full_text":"https://origin.rootz.global/static/filing/0001493152-25-000294.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ibed to such term in Section 4.01(c). Liens shall mean a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction or adverse claim of a third party. Material Adverse Effect has the meaning ascribed to such term in Section 3.01(b). Maximum Offering Amount means an aggregate Subscription Amount of up to $1,000,000 equating to an aggregate maximum principal amount of Notes","filed_date":"2024-12-02","accession":"0001493152-24-048330","full_text":"https://origin.rootz.global/static/filing/0001493152-24-048330.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"ector, and has indicated a willingness to continue to serve as a director, if elected. If the nominee becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our board of directors. **Nominee for Election as Class III Director** The following table identifies our nominee for director and his age as of November 19, 2024, and the following biography sets forth his principal occu","filed_date":"2024-11-19","accession":"0001493152-24-046819","full_text":"https://origin.rootz.global/static/filing/0001493152-24-046819.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":62,"context":"on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investm","filed_date":"2024-07-30","accession":"0000950170-24-087886","full_text":"https://origin.rootz.global/static/filing/0000950170-24-087886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"late by Geoffrey Ling, each dated October 16, 2023 and each reporting one transaction. Item 11. Executive Compensation. The following is a discussion and analysis of compensation arrangements of our named executive officers. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual compen","filed_date":"2024-07-30","accession":"0000950170-24-087886","full_text":"https://origin.rootz.global/static/filing/0000950170-24-087886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"y jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. | -9- | | Section 5.02 Authorization, Enforcement, Compliance with Other Instruments. The Company has the requisite corporate power and authority to enter into and perform its obligations under this","filed_date":"2024-03-15","accession":"0001493152-24-010134","full_text":"https://origin.rootz.global/static/filing/0001493152-24-010134.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"Company in any capacity at the time of sale. “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “Person” means a","filed_date":"2024-01-17","accession":"0000950170-24-005029","full_text":"https://origin.rootz.global/static/filing/0000950170-24-005029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"Company in any capacity at the time of sale. “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “Purchase Price”","filed_date":"2023-05-19","accession":"0000950170-23-023264","full_text":"https://origin.rootz.global/static/filing/0000950170-23-023264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"uating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; | | | | | | reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be paid or awarded to our non-employee board members; | | 1","filed_date":"2023-05-01","accession":"0001193125-23-128936","full_text":"https://origin.rootz.global/static/filing/0001193125-23-128936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"ctors, and have indicated a willingness to continue to serve as directors, if elected. If the nominees become unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our board of directors. **Nominees for Election as Class II Directors** The following table identifies our nominees for directors and their ages as of May 1, 2023, and the following biographies set forth their principal","filed_date":"2023-05-01","accession":"0001193125-23-128936","full_text":"https://origin.rootz.global/static/filing/0001193125-23-128936.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"se in cellular therapeutic development and manufacturing to generate revenues by providing contract manufacturing and development services to third parties; • the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries; • our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the in","filed_date":"2023-03-31","accession":"0000950170-23-011440","full_text":"https://origin.rootz.global/static/filing/0000950170-23-011440.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investm","filed_date":"2023-03-31","accession":"0000950170-23-011440","full_text":"https://origin.rootz.global/static/filing/0000950170-23-011440.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"Company in any capacity at the time of sale. “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “Purchase Price”","filed_date":"2023-03-23","accession":"0000950170-23-009338","full_text":"https://origin.rootz.global/static/filing/0000950170-23-009338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"01. Section 1.21 Initial Registration Statement shall have the meaning set forth in Section 7.01(a). Section 1.22 Market Price shall have the meaning set forth in Section 1.39. - 2 - Section 1.23 Material Adverse Effect shall mean any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the t","filed_date":"2022-09-15","accession":"0001193125-22-245623","full_text":"https://origin.rootz.global/static/filing/0001193125-22-245623.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"with the laws, orders, rules, regulations and directives issued or administered by such jurisdictions, except where the failure to be in compliance would not, individually or in the aggregate, have a Material Adverse Effect (as defined below). (g) Foreign Qualification of the Company. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction where the ownership o","filed_date":"2022-09-08","accession":"0001193125-22-240629","full_text":"https://origin.rootz.global/static/filing/0001193125-22-240629.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"ctors, and have indicated a willingness to continue to serve as directors, if elected. If the nominees become unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by our board of directors. **Nominees for Election as Class I Directors** The following table identifies our nominees for directors and their ages as of June 3, 2022, and the following biographies set forth their principal","filed_date":"2022-06-03","accession":"0001193125-22-167393","full_text":"https://origin.rootz.global/static/filing/0001193125-22-167393.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"tements about: | | | the success, cost, timing and potential indications of our cellular therapy candidate development activities and clinical trials | | | | | the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries | | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the","filed_date":"2022-03-31","accession":"0001564590-22-013004","full_text":"https://origin.rootz.global/static/filing/0001564590-22-013004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investm","filed_date":"2022-03-31","accession":"0001564590-22-013004","full_text":"https://origin.rootz.global/static/filing/0001564590-22-013004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ne Form 4 filing by Mr. Eschenbach, dated December 2, 2021, reporting one transaction. Item 11. Executive Compensation. The following is a discussion and analysis of compensation arrangements of our named executive officers. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual compen","filed_date":"2022-03-31","accession":"0001564590-22-013004","full_text":"https://origin.rootz.global/static/filing/0001564590-22-013004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"tial business combination with only a single entity, our lack of diversification may: | | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and | | | | | cause us to depend on the marketing and sale of a single product or limited number of products","filed_date":"2021-03-04","accession":"0001213900-21-013228","full_text":"https://origin.rootz.global/static/filing/0001213900-21-013228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"nitial business combination with only a single entity, our lack of diversification may: | | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and | | | | | cause us to depend on the marketing and sale of a single product or limited number of products o","filed_date":"2020-03-24","accession":"0001213900-20-007185","full_text":"https://origin.rootz.global/static/filing/0001213900-20-007185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"relating to the preparation of the Transaction Documents and the enforcement of the Purchasers rights, remedies and powers under this Agreement, the Notes and/or the other Transaction Documents. (ll) Material Adverse Effect means a material adverse effect on (a) the business, assets, property, operations, or condition (financial or otherwise) of the Company, (b) the validity or enforceability of this Agreement or any of","filed_date":"2026-09-28","accession":"0001493152-26-044421","full_text":"https://origin.rootz.global/static/filing/0001493152-26-044421.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"e expertise in cellular therapeutic development and manufacturing to generate revenues by providing contract manufacturing and development services to third parties; the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries; our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the indications","filed_date":"2024-07-30","accession":"0000950170-24-087886","full_text":"https://origin.rootz.global/static/filing/0000950170-24-087886.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":96,"match_count":12,"context":"wnership, lease or operation of properties or the conduct of its business requires such qualification or license, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect. 3.2 Authorization; No Contravention. The execution, delivery and performance by the Borrower of each Loan Document to which it is party have been duly authorized by all necessary organizational acti","filed_date":"2023-06-21","accession":"0000950170-23-029159","full_text":"https://origin.rootz.global/static/filing/0000950170-23-029159.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"andidates, such as substantial delays in clinical trials risks associated with our ongoing and planned clinical trials, such as unexpected data or clinical site activation rates or clinical trial enrollment rates that are lower than expected our therapeutic candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory appro","filed_date":"2021-11-12","accession":"0001564590-21-056724","full_text":"https://origin.rootz.global/static/filing/0001564590-21-056724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"| | | | | | | | the size of the markets for our therapeutic candidates and biomaterials products, and our ability to serve those markets; | | | | | | | | | | timing of the initiation, enrollment and completion of any potential clinical trials in the United States and foreign countries; | | | | | | | | | | our ability to obtain and maintain regulatory approval of our therapeutic cand","filed_date":"2025-11-14","accession":"0001493152-25-023467","full_text":"https://origin.rootz.global/static/filing/0001493152-25-023467.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":88,"match_count":11,"context":"uating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; | | | | | reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be paid or awarded to our non-employee board members; | | | |","filed_date":"2024-11-19","accession":"0001493152-24-046819","full_text":"https://origin.rootz.global/static/filing/0001493152-24-046819.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":88,"match_count":11,"context":"wnership, lease or operation of properties or the conduct of its business requires such qualification or license, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect. 3.2 Authorization; No Contravention. The execution, delivery and performance by the Borrower of each Loan Document to which it is party have been duly authorized by all necessary organizational act","filed_date":"2023-08-25","accession":"0001193125-23-221469","full_text":"https://origin.rootz.global/static/filing/0001193125-23-221469.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":88,"match_count":11,"context":"wnership, lease or operation of properties or the conduct of its business requires such qualification or license, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect. 3.2 Authorization; No Contravention. The execution, delivery and performance by the Borrower of each Loan Document to which it is party have been duly authorized by all necessary organizational acti","filed_date":"2023-05-16","accession":"0000950170-23-022503","full_text":"https://origin.rootz.global/static/filing/0000950170-23-022503.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":87,"match_count":9,"context":"lly-owned merger subs and Celularity LLC (formerly known as Celularity Inc.), or Legacy Celularity. Pursuant to the terms of the Merger Agreement, we effected the business combination through the (a) merger of our wholly-owned merger sub with and into Legacy Celularity with Legacy Celularity surviving as our wholly-owned subsidiary and (b) immediately following the first merger and as part of the same over","filed_date":"2023-03-31","accession":"0000950170-23-011440","full_text":"https://origin.rootz.global/static/filing/0000950170-23-011440.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":80,"match_count":10,"context":"uating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; | | | | | reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be paid or awarded to our non-employee board members; | | | |","filed_date":"2025-11-07","accession":"0001493152-25-021208","full_text":"https://origin.rootz.global/static/filing/0001493152-25-021208.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"| | | | | | the size of the markets for our therapeutic candidates and biomaterials products, and our ability to serve those markets; | | | | | | | | | | the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries; | | | | | | | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates","filed_date":"2025-05-08","accession":"0001641172-25-009319","full_text":"https://origin.rootz.global/static/filing/0001641172-25-009319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"tements about: | | | the success, cost, timing and potential indications of our cellular therapy candidate development activities and clinical trials | | | | | the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries | | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the","filed_date":"2022-05-16","accession":"0001564590-22-020422","full_text":"https://origin.rootz.global/static/filing/0001564590-22-020422.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"| | | | | | the size of the markets for our therapeutic candidates and biomaterials products, and our ability to serve those markets; | | | | | | | | | | the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries; | | | | | | | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates","filed_date":"2026-09-29","accession":"0001493152-26-044892","full_text":"https://origin.rootz.global/static/filing/0001493152-26-044892.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":79,"match_count":8,"context":"ducted and as presently proposed to be conducted. (d) **Key Employees** means Robert Sambursky and any executive-level employee (including division director and vice president-level positions). (e) **Material Adverse Effect** means a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, prospects or results of operations of the Company. (f) **Person**","filed_date":"2025-08-12","accession":"0001641172-25-023231","full_text":"https://origin.rootz.global/static/filing/0001641172-25-023231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":79,"match_count":8,"context":"eries B and Series X preferred stock into common stock | | | 550,113 | | | | - | | | | Cancellation of treasury stock | | | 256 | | | | - | | | | Non-cash assets acquired from the merger with GX Acquisition Corp. | | | 163 | | | | - | | | | Warrant liability assumed from the merger with GX Acquisition Corp. | | | 59,202 | | | | - | | | | Issuance of common stock as pay","filed_date":"2021-11-12","accession":"0001564590-21-056724","full_text":"https://origin.rootz.global/static/filing/0001564590-21-056724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nt services to third parties; | | | | the size of the markets for our therapeutic candidates and biomaterials products, and our ability to serve those markets; | | | | timing of the initiation, enrollment and completion of any potential clinical trials in the United States and foreign countries; | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of","filed_date":"2025-08-29","accession":"0001641172-25-026056","full_text":"https://origin.rootz.global/static/filing/0001641172-25-026056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"statements about: • the success, cost, timing and potential indications of our cellular therapy candidate development activities and clinical trials; • the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries; • our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the in","filed_date":"2022-11-10","accession":"0000950170-22-024523","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024523.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"tements about: | | | the success, cost, timing and potential indications of our cellular therapy candidate development activities and clinical trials | | | | | the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries | | | | | our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the","filed_date":"2022-08-09","accession":"0001564590-22-028775","full_text":"https://origin.rootz.global/static/filing/0001564590-22-028775.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":68,"match_count":6,"context":"tic candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences difficulties arising from our third-partylicenses, or supply-chainor manufacturing challenges our ability to obtain adequate financing to fund our planned clinical trials and other expenses risks fr","filed_date":"2021-11-12","accession":"0001564590-21-056724","full_text":"https://origin.rootz.global/static/filing/0001564590-21-056724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"CELU","company":"Celularity Inc","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":65,"match_count":5,"context":"tic candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. • Our relationship wi","filed_date":"2022-11-10","accession":"0000950170-22-024523","full_text":"https://origin.rootz.global/static/filing/0000950170-22-024523.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"296d672a03c70f331e436f286672d566ff82c1fb4ac86c42255a6e5cae25e74c","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"2c8636fcb94455a6b9317b7bbf4d7c6efd681cb34fa75038ee661a09323129e3","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}